Cellectis SA at Barclays Global Healthcare Conference Transcript
Good afternoon. My name is Gena Wang. I'm a senior biotech analyst at Barclays. Thank you for joining Barclays' Global Healthcare Conference. It is my great pleasure to introduce our next presenting company, Cellectis. With us today, we have Andre Choulika, Chief Executive Officer and a Board Director.
Andre, maybe before I dive into specific questions, do you want to give a brief overview of the company?
Of course. Yes, sure. Quickly, because I think that you probably have a list of questions. For the one that doesn't know us, Cellectis is a cell and gene therapy company that has been founded a long time ago on the concept of gene editing. I think we're the first gene editing company in the world. But currently, we're focusing essentially on allogeneic CAR-T.
We have a series of assets in the clinic today, one called UCART22 in acute lymphoblastic leukemia in a trial called AMELI -- BALLI-01. But we're going
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
